STOCK TITAN
  1. Home
  2. News
  3. CGEN

Compugen Ltd - CGEN STOCK NEWS

Welcome to our dedicated news page for Compugen (Ticker: CGEN), a resource for investors and traders seeking the latest updates and insights on Compugen.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Compugen's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Compugen's position in the market.

News
Compugen will be Eligible to Receive $10 Million Milestone Payment upon Dosing of First Patient in AstraZeneca Phase 3 Rilvegostomig Trial in Biliary Tract Cancer
Rhea-AI Summary
Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) to receive $10 million milestone payment from AstraZeneca for dosing the first patient in Phase 3 trial of rilvegostomig, a PD-1/TIGIT bispecific antibody
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.08%
Tags
clinical trial
-
News
Compugen to Host Conference Call to Discuss Exclusive License Agreement with Gilead for COM503, Novel Immuno-Oncology Pre-Clinical Program Harnessing IL-18 Biology
Rhea-AI Summary
Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) announced a conference call to discuss the exclusive license agreement with Gilead for the development and commercialization of its anti-IL-18 binding protein program, including COM503, a potential first-in-class high affinity antibody targeting IL-18 binding protein with the potential to treat multiple tumor types.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
173.97%
Tags
conferences
-
News
Gilead and Compugen Announce Exclusive License Agreement for Novel Pre-Clinical Immunotherapy Program
Rhea-AI Summary
Gilead Sciences, Inc. (Nasdaq: GILD) announced an exclusive licensing agreement with Compugen Ltd. (Nasdaq: CGEN) for a pre-clinical antibody program against IL-18 binding protein, including the COM503 drug candidate. The deal involves a $60 million upfront payment and $30 million milestone payment with a total deal value of up to $848 million.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
173.97%
Tags
none
News
Compugen Reports Third Quarter 2023 Results
Rhea-AI Summary
Compugen Ltd. announced the progress of rilvegostomig, AstraZeneca's PD-1/TIGIT bi-specific derived from Compugen's COM902, into Phase 3 as adjuvant therapy for biliary tract cancer. Enrollment was completed in a proof-of-concept study for metastatic colorectal cancer. The company presented new clinical data at SITC 2023, reinforcing the anti-tumor activity of COM701 and initial data suggesting PVRL2 as a potential biomarker. Pre-clinical data also highlighted the potential of COM503's antibody approach to treat cancer. Financial results showed cash, cash equivalents, and cash investments of approximately $57.5 million as of September 30, 2023, expected to fund operations through the end of 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.69%
Tags
earnings
-
News
Compugen's COM701 (anti-PVRIG) Mediates Anti-Tumor Activity in Patients Typically Not Responding to Immunotherapy
Rhea-AI Summary
Compugen Ltd. announced data presented at the Annual Meeting of the Society for Immunotherapy of Cancer (SITC), reinforcing previous data suggesting COM701 mediated anti-tumor activity in patients typically not responding to immunotherapy. Initial data also showed the association between baseline PVRL2 levels and clinical benefit, suggesting the potential of PVRL2 as a predictive biomarker. The company is continuing to assess this association in an ongoing proof-of-concept study in platinum resistant ovarian cancer.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.7%
Tags
none
-
News
Compugen Announces Receipt of Nasdaq Minimum Bid Price Notification
Rhea-AI Summary
Compugen Ltd. received a notification letter from Nasdaq stating that its ordinary shares failed to maintain a minimum bid price of $1.00 over the previous 30 consecutive business days. The company has 180 calendar days to regain compliance with the Minimum Bid Price Requirement. If compliance is not achieved by May 1, 2024, the company may be eligible for an additional 180-day grace period. If still non-compliant after that, the company's ordinary shares may be subject to delisting from the Nasdaq Capital Market.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
News
Compugen to Present New Data at SITC 2023 Suggesting Leading Edge of Anti-IL18 Binding Protein Antibody, COM503, in Treating Cancer
Rhea-AI Summary
Compugen Ltd. will present new data on its lead pre-clinical asset COM503, a potential first-in-class anti-IL18BP antibody, at the 38th Annual Meeting of the Society for Immunotherapy of Cancer. The data shows that the antibody inhibits tumor growth, increases functional immune cells, and reshapes the tumor microenvironment for a potent anti-tumor immune response. The company's approach has a better therapeutic window compared to engineered cytokines.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
10.14%
Tags
conferences
-
News
Compugen to Release Third Quarter 2023 Results on Tuesday, November 7, 2023
Rhea-AI Summary
Compugen Ltd. will release its Q3 2023 financial results on November 7, 2023, and provide a corporate update. Management will discuss data presented at the Annual Meeting of the Society for Immunotherapy of Cancer.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.71%
Tags
earnings
-
News
Compugen to Present at Single Cell Genomics 2023 Meeting
Rhea-AI Summary
Compugen Ltd. to present innovative single-cell approaches and high resolution single cell spatial transcriptomics data at Single Cell Genomics 2023 meeting. The data will provide a deeper understanding of PVRIG's unique biology and rationale for targeting PVRIG in tumors not responding to immunotherapy.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.17%
Tags
conferences
News
Compugen Expands Intellectual Property with New Japanese Patent for the Triple Combination of any Anti-PVRIG, TIGIT and PD-1 Antibody for the Treatment of Cancer
Rhea-AI Summary
Compugen Ltd. has been granted a patent in Japan for treating cancer with a triple combination of antibodies. The patent strengthens Compugen's position in blocking three pathways of the DNAM-1 axis. The company is executing a clinical strategy to evaluate the benefit of its triple immunotherapy combination to treat cancer patients.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.23%
Tags
none
Stock CGEN logo
Compugen Ltd

Nasdaq:CGEN

CGEN Rankings

#3882 Ranked by Market Cap
#3776 Ranked by Stock Gains
N/A Ranked by Dividends

CGEN Stock Data

202.23M
84.69M
5.38%
13.71%
2.34%
Biological Product (except Diagnostic) Manufacturing
Manufacturing
Link
Israel
Holon

About CGEN

compugen is a leading drug discovery company focused on therapeutic proteins and monoclonal antibodies to address important unmet needs in the fields of immunology and oncology. the company utilizes a broad and continuously growing integrated infrastructure of proprietary scientific understandings and predictive platforms, algorithms, machine learning systems and other computational biology capabilities for the in silico (by computer) prediction and selection of product candidates, which are then advanced in its pipeline program. the company's business model includes collaborations covering the further development and commercialization of product candidates at various stages from its pipeline program and various forms of research and discovery agreements, in both cases providing compugen with potential milestone payments and royalties on product sales or other forms of revenue sharing. compugen’s wholly-owned u.s. subsidiary located in south san francisco is developing monoclonal antib